Dr. Lam Discusses Agents for ROS1-Mutated NSCLC

Vincent Lam, MD
Published: Friday, Nov 03, 2017



Vincent Lam, MD, assistant professor, The University of Texas MD Anderson Cancer, discusses agents to target ROS1-mutated non-small cell lung cancer (NSCLC).

Not all ALK inhibitors will benefit patients with ROS1-mutated NSCLC, explains Lam.

The agent that is furthest in development is lorlatinib which was investigated in a phase II trial. The ROS1 cohort demonstrated good response for patients who had been previously treated or were treatment-na
SELECTED
LANGUAGE


Vincent Lam, MD, assistant professor, The University of Texas MD Anderson Cancer, discusses agents to target ROS1-mutated non-small cell lung cancer (NSCLC).

Not all ALK inhibitors will benefit patients with ROS1-mutated NSCLC, explains Lam.

The agent that is furthest in development is lorlatinib which was investigated in a phase II trial. The ROS1 cohort demonstrated good response for patients who had been previously treated or were treatment-na

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x